Evidence map›Paper›PMID 42548059›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2026

Peptide exchange-competent class I MHC molecules produced in eukaryotic cells for rapid production of MHC multimers.

Vasanthi Ramachandiran, John C Shires, Richard A Willis, Ge Bai, Donielle L Bell, Lixia Han, Tamara R Kazarian, Fred O Ede, Oskar Laur, Sujin Lee and 2 more

Abstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Vasanthi RamachandiranEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA, United States.
John C ShiresEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA, United States.
Richard A WillisEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA, United States.
Ge BaiEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA, United States.
Donielle L BellEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA, United States.
Lixia HanEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA, United States.
Tamara R KazarianEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA, United States.
Fred O EdeEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA, United States.
Oskar LaurEmory Custom Cloning Core Facility, Emory University School of Medicine, Atlanta, GA, United States.
Sujin LeeDepartment of Pediatrics, Center for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Emory University School of Medicine, Atlanta, GA, United States.
Dale L LongEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA, United States.
John D AltmanEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA, United States.ORCID 0000-0001-9733-2359

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
Tetramer Research & Development Contract (Influenza)75N93020D00005 · NIAID · EMORY UNIVERSITY · PI ALTMAN, JOHN · 2020 to 2025
$18.3M
cGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of a Nanoparticle Based HIV Envelope Vaccine75N93022D00005 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI HASSELL, THOMAS · 2022 to 2025
$8.0M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1M
NHLBI NIH HHS 75N92020D00005NIAID NIH HHS 75N93022D00005NIAID NIH HHS HHSN272201300006CNIAID NIH HHS P30 AI050409NIDA NIH HHS 75N95020D00005NIH HHS 75N93020D00005NIH HHS 75N93023D00005NIH HHS 75N99020D00005NIH HHS HHSN272201300006CNIH HHS P30AI050409NIH HHS P51 OD011132NIH HHS P51OD011132
6 · The paper itself

Abstract

Class I MHC peptide (MHC-Ip) multimers are well-established reagents that detect antigen-specific T cells. The classical method for production of MHC-Ip multimers begins with the expression of MHC heavy chains (HCs) and β2-microglobulin (β2m) subunits as inclusion bodies in Escherichia coli and is followed by denaturant solubilization, in vitro folding in the presence of a defined peptide ligand, and purification by size exclusion chromatography. This protocol is labor intensive, difficult to scale, and represents a significant bottleneck in application of the technology. Herein, we present a novel method for the expression in eukaryotic cells of secreted peptide exchange-competent class I MHC proteins in their native conformation. In this method, expression constructs are engineered as bimolecular complexes composed of an MHC HC and a β2m molecule covalently linked at its amino terminus to an MHC-binding peptide through a flexible peptide linker containing a defined protease site. Upon proteolysis, the original peptide occupant of the MHC binding site dissociates and is easily replaced with a synthetic peptide. When leucine zippers are added to the carboxyl terminus of each subunit, protease cleavage of the linker results in a stable HC/β2m complex that can be isolated and stored for subsequent peptide loading. Using this method, we have produced homogeneous MHC-Ip complexes for 25 class I MHC alleles and demonstrated that tetramers produced in this way are equivalent to conventionally produced tetramers for T-cell staining.

Indexed as

Eukaryotic CellsHistocompatibility Antigens Class IPeptidesbeta 2-MicroglobulinEscherichia coliHumansProtein MultimerizationT-Lymphocytesbeta 2-MicroglobulinHistocompatibility Antigens Class IPeptidesMHC-I peptide complexesMHC multimersT-cell assays

Identifiers

PMID42548059
PMCPMC13433367

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.